Items Tagged ‘avastin’

May 12th, 2016

Avastin®/Camptosar® Improves Outcomes Compared with Temodar® in Glioblastoma

By

The treatment combination consisting of Avastin (bevacizumab) plus Camptosar (irinotecan) improves time to cancer progression compared to treatment with Temodar (temozolomide) in patients with newly diagnosed glioblastoma. These results were recently published in the Journal of Clinical Oncology. Glioblastoma is an extremely aggressive form of brain cancer. Standard therapy includes surgery to remove as much […]

View full entry

Tags: avastin, bevacizumab, Brain Cancer, Campostar, glioblastoma, irinotecan, News, nonmethylated O6-methylguanine–DNA methyltransferase promotor, Temodar, temozolomide


September 29th, 2015

No Benefit with Addition of Onartuzumab to Taxol® with or without Avastin® in Triple-Negative Breast Cancer

By

The addition of the targeted therapy onartuzumab to Taxol® (paclitaxel) with or without Avastin® (bevacizumab) does not appear to help control disease or improve survival in patients with metastatic triple-negative breast cancer. These findings were published in the Annals of Oncology. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are […]

View full entry

Tags: avastin, Breast Cancer, metastatic, Metastatic Breast Cancer, Onatuzumab, Taxol, triple negative


July 1st, 2015

Rintega® Improves Survival in Patients with Glioblastoma Multiforme

By

The immunotherapy drug Rintega® (rindopepimut) appears to improve survival among patients with relapsed glioblastoma multiforme (GBM) brain cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical Oncology. Glioblastoma multiforme is one of the most common and […]

View full entry

Tags: avastin, bevacizumab, Brain Cancer, clinical trial, EGFRvIII, gbm, General Brain Cancer, glioblastoma multiforme brain cancer, News, rindopepimut, Rintega


April 29th, 2015

Combination of Avastin®, Taxol®, and Carboplatin Improves Survival in Recurrent Platinum-Sensitive Ovarian Cancer

By

The addition of Avastin® (bevacizumab) to Taxol® (paclitaxel) and carboplatin for the treatment of recurrent platinum-sensitive ovarian cancer appears to improve survival. These findings were presented at the 2015 Annual Meeting on Women’s Cancer, March 28–31, in Chicago, Illinois. Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more […]

View full entry

Tags: avastin, bevacizumab, carboplatin, clinical trial, News, Ovarian Cancer, paclitaxel, platinum sensitive, Taxol


January 15th, 2015

Aggressive Chemotherapy Doubles Survival of Patients with Metastatic Colon Cancer

By

According to the results of a clinical trial presented at the 2015 Gastrointestinal Cancers Symposium in San Francisco, treatment of patients with metastatic colorectal cancer with a four-drug chemotherapy regimen plus Avastin® (bevacizumab) doubles survival when compared to a standard three drug regimen and Avastin. According to estimates from the American Cancer Society, more than […]

View full entry

Tags: avastin, bevacizumab, Colon Cancer, colorectal cancer, crc, folfiri, FOLFOX, News, Stage IV (D)/Relapsed Colon Cancer


December 2nd, 2014

Avastin Approved by the FDA for Recurrent Ovarian Cancer

By

The FDA approval was based on the results of the AURELIA clinical trial, which involved 361 women with ovarian cancer that had recurred less than 6 months after their most recent platinum-based chemotherapy treatment. The   phase III trial compared chemotherapy alone or in combination with Avastin. Each year in the United States, roughly 22,000 women […]

View full entry

Tags: avastin, fda, News, Ovarian Cancer, Recurrent Ovarian Cancer


October 20th, 2014

Second-line Avastin Improves Progression-Free Survival in Advanced HER2-Negative Breast Cancer

By

Adding Avastin® (bevacizumab) to chemotherapy in second-line treatment of advanced HER2-negative breast cancer improves progression-free survival. Results of the phase III TANIA trial evaluating the role of Avastin® in advanced breast cancer were recently reported in The Lancet Oncology journalby von Minckwitz et al at The University Women’s Hospital, Frankfurt, Germany. The TANIA trial is […]

View full entry

Tags: avastin, bevacizumab, Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer


June 20th, 2014

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer

By

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX or FOLFIRI) regimens led to a new benchmark median survival time of 29 months. The results presented as ASCO were from the […]

View full entry

Tags: asco, avastin, Colon Cancer, colorectal cancer, erbitux, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer